{"groups":[{"description":"Bortezomib 1.3 milligram (mg) per meter\\^2 (m\\^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).","id":"FG000","title":"Bortezomib and Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Unresolved toxicity after 2 weeks"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}